RU2334499C2 - Method of treatment of liver diseases - Google Patents

Abstract

FIELD: medicine.

SUBSTANCE: medication therapy of liver diseases is carried out in combination with abdominal decompression. Method ensures enhancing secretion by intestinal mucosa goblet cells of mucopolysaccharides, which form common mucous covering of enterocites allowing for binding and taking out toxins without using enterosorbents.

EFFECT: better treatment.

2 dwg, 2 tbl, 5 ex

Description

The invention relates to medicine and veterinary medicine and relates to the treatment of liver diseases.

Four groups of the main methods of treating liver diseases are known. The first group includes methods involving etiopathogenetic treatment with various chemical-pharmaceutical and immunobiological preparations, depending on the etiology of the disease. So, to correct hemodynamics and improve liver microcirculation, vasopressin is administered intravenously (Valla D., Girod Lee SS et al. Lakt of vasopressin action on splanchnic hemodinamics during bleeding, conscious, portal hypertensive rats. Hepatology. 1988, - 810 p.), Nitroglycerin (Millikan WJ, Warren WD, Henderson JM et al. The Emory prospective randomized trial: selective versus non selective shunt to control variccal bleeding. Ten year follow-up. Ann. Surg. 1985, 201; 712), somatostatin and its analogues ( Gines A., Salmeron JM Gines somatostatin on real function in cirrhos. 1992, 103; Primignan M., Adreoni B. Carpinel Sclerotherapy plus octreotide versus sclerotheraf the prevention of early rebleeding from esophages randomized double-blind, placebo-controled r trial. Hepatology , 1995, 21, 1322), as well as verapamil (Moreau R., Lee S., Hadengue A. e t al. Hemodynamic effect of a clonidine-induced decrease in sympathetic lone in patients with cirrhosis. Hepatology, 1987, 7, 149). To improve the venous outflow, reduce the cytolytic and mesenchymal inflammatory syndrome and simplify the application of the drug, oral administration of sulodexide VESSEL DU F (RU 2180227, A61K 31/727, 35/38; A61P 1/16, 2002) or moxonidine (RU 2219930, A61K 31 / 505, A61P 1/16, 2003).

This group also includes methods involving drug therapy with several drugs that have a synergistic effect. So, in the treatment of chronic viral hepatitis, Roncoleukin and Corbiculin are simultaneously prescribed (RU 2265447, A61K 35/56, A61P 1/16, 2005), and in the treatment of patients with chronic glomerulonephritis, Mildronate is prescribed, and then Mildronate is used while taking dipyridamole (RU 2262337, A61K 31/15, 31/506, A61P 13/12, 2005).

However, these methods are not effective enough, since they do not always have a complex drug effect on the pathogenetic processes of the disease.

The second group includes methods based on extracorporeal hemocorrection. So, in the treatment of patients with hematochromatosis, plasmapheresis is performed with plasma elimination to remove iron, followed by correction with albumin and reopoliglyukin (Loginov A.S., Tokarev Yu.N., Settarova D.A., Sukhareva V.V. Modern diagnostics and methods treatment of hereditary hemachromatosis. // Ter. Archive. 1988, No. 10, pp. 117-121). It is advisable to combine extracorporeal hemocorrection with physiotherapy, for example, with external laser irradiation of the thymus, spleen, right and left lobes of the liver with a radiation power density of 13 mW / cm ² (RU 2146543, A61N 5/067, A61M 1/36, 1/38, 2000; RU 2146948, A61M 1/36, A61N 5/06, 2000). In the treatment of chronic liver diseases with HBs Ag carriage, plasmapheresis is combined with low-intensity helioneon laser blood irradiation and glucocorticosteroid therapy (RU 2144836, A61N 5/06, A61M 1/34, 2000). This group also includes a method of treating liver diseases, which consists in conducting hemosorption sessions (Lopukhin Yu.M. Hemosorption. 2nd ed. M: Medicine. 1985, 288 p.).

However, these methods quite often give adverse reactions and various complications.

The third group includes methods involving physiotherapeutic treatment of liver diseases. Physiotherapeutic treatment can be carried out by vibroacoustic exposure with a changing frequency and adjustable duty cycle of pulses generated, for example, by the Vitafon apparatus. Variants of the method provide for an individual choice of the frequency range and the vibroacoustic impact circuit. In addition, it is possible to carry out additional physiotherapeutic effects by heating the patient’s body at the location of the vibroacoustic head using a laser (Fedorov V.A. Vitafon. Treatment and prevention of diseases. // St. Petersburg: Vita Nova. 2000. - 256 p.). When exposed to this device, an increase in blood outflow occurs, as a result of which the portal system is unloaded. As a result, the coefficient of outflow-blood flow increases, approaching the norm. In this way, normal blood circulation is restored, drug delivery is improved, endogenous interferonogenesis is possibly induced (A. Kovelenov. The effect of vibroacoustic therapy on blood flow in the liver in chronic viral hepatitis. The use of vibroacoustic therapy in the treatment of chronic hepatitis. // Vibroacoustics in medicine. - St. Petersburg ., 2000. However, when using the Vitafon apparatus, chronic pathological processes in the liver may aggravate and signs of a cytolytic syndrome may increase.

The fourth group of methods involves the treatment of liver diseases through a synergistic combination of drug therapy with physiotherapeutic effects. This idea underlies the method of physiotherapeutic treatment of liver diseases, including stimulation of the diaphragm by direct electric current with a frequency of 30-60 pulses per minute daily for 10-14 days for 15-45 minutes in combination with drug therapy using mesim forte, cerucal, Toko-ferol acetate, vitamins of groups B and C (RU 2232609, A61N 1/36, 2004).

Of the methods of this group, the most famous is the combination of drug treatment with vitafonotherapy, since the vibroacoustic method, due to its proximity to the natural regulatory mechanisms of the human body, can be used with almost all other treatment methods. It is very well combined with drug therapy, relieving, in particular, vasospasm and restoring blood and lymph flow, as a result of which drugs more easily reach the diseased organ (Fedorov V.A. Vitafon. Treatment and prevention of diseases. // St. Petersburg: Vita Nova 2000. - 256 pp .; see also: Vitafon - a little about the Russian miracle. // Internet address: http://vitafon.ok.ru/).

However, the methods of this group are not sufficiently effective and inconvenient in operation, especially in the treatment of animals, since they require fixing emitters of physiotherapeutic effects at certain points on the patient's body.

An object of the invention is to increase the medical effectiveness of the method and the convenience of its implementation.

The solution to this problem lies in the fact that in a method of treating liver and kidney diseases, which involves drug therapy in combination with a physiotherapeutic effect, abdominal decompression is performed as a physiotherapeutic effect.

Conducting blood pressure for the specified purpose is new.

A causal relationship between the changes made and the technical result achieved is an increase in blood flow in the intestinal vessels under blood pressure conditions, which leads to an increase in the transfer of medicinal substances and end products of interaction with them into the intestinal cavity, their excretion and binding. In this case, medicinal substances and their derivatives bind to mucus secreted by goblet cells due to the mucopolysaccharide nature of mucin, which is intensively excreted in blood pressure conditions.

When carrying out abdominal decompression, the vacuum is maintained in the commonly used range from -0.02 to -0.15 kg / cm ² (RU 2051630, A61B 17/42, A61M 1/00, 1996). Usually prescribed 10-15 daily sessions of blood pressure (in combination with medication), including 10-15 cycles of dilution for 1-3 minutes with a pause of 1 minute.

Figure 1 shows the design of the apparatus for blood pressure in animals; figure 2 shows the rheograms of blood flow in the liver for example 6. In table 1 illustrates the dynamics of changes in blood serum in humans in the treatment of liver diseases; table 2 presents the indicators of the effectiveness of the treatment of liver diseases in animals to examples 4, 5.

As a technical means of implementing a physiotherapeutic procedure in the treatment of people, it is possible to use any of the known devices for abdominal decompression. Moreover, the apparatus made according to the patent RU 2143257, A61H 9/00, 1999 is most preferred.

As a means of implementing the method in the treatment of animals, it is convenient to use the apparatus depicted in figure 1. The apparatus consists of a pressure chamber formed by a pallet 1 and a cap 2 sealed on it, made of a transparent material (for visual observation of the animal). The pallet 2 is made with the possibility of removal or reclining for sanitary treatment. The front wall of the cap 2 is equipped with a flange 3 with a cuff 4 made of an airtight fabric. An elastic fastener 5 is made on the outer edge of the cuff 4 to create an airtight seal on the part of the animal’s body located in the pressure chamber. As a fastener 5, an elastic belt can be used.

On the back cover of the cap 2 there is a fitting 6 for connecting the pressure chamber to the vacuum system. A bracket 7 is mounted on top of the cap 2 on top of which the end of the harness strap 8 is fixed, which serves to fix the animal in order to prevent it from being drawn into the pressure chamber under vacuum. The bracket 7 serves simultaneously as a handle for carrying the device.

The pressure chamber is treated with a disinfectant solution, the rear part of the animal’s body, fixed by the harness 8, is placed in it, the pressure chamber is sealed with the fastener 6 of the cuff 5 and a vacuum is created in it according to the required mode.

Examples 1-3 illustrate the use of the proposed method for treating people.

EXAMPLE 1. Patient I., 52 years old. Diagnosis: steatohepatitis, chronic cholecystitis, chronic pancreatitis in the phase of moderate exacerbation. From the anamnesis: over the past 15 years I have been drinking alcohol daily. Complaints of nausea, belching, loss of appetite, a feeling of heaviness in the right hypochondrium and epigastric region, bloating, unrelated periodic stitching pains behind the sternum, palpitations. Objectively: increased venous pattern on the chest against the background of subictericity of the skin and visible mucous membranes; the borders of the heart are extended to the left by 1.5 cm. During auscultation, 1 tone at the top and at the Botkin point is weakened, a gentle systolic murmur is heard in the projection of these points. Hard breathing with a frequency of 16 per min ^-1 , no wheezing. When examining the abdominal cavity: the abdomen is of normal shape, on palpation it is soft, painless, the liver is enlarged by 6 cm, the edge of the liver is smooth, elastic, rounded, the spleen is not palpated, the size of the spleen is not enlarged percussion. The kidneys are not palpable, no peripheral edema. In the study of peripheral blood, the content of hemoglobin, erythrocytes, leukocytes, platelets did not differ from normal values, increased ESR - 25 mm / h. Biochemical blood test: total protein - 73 g / l, albumin - 54%, gamma globulins - 36.3%, mercuric chloride test - 1.6 ml, ALT - 17.1 mmol / l, bilirubin - 24.8 mmol / l, ESR - 11 mm / h, CEC - 19.1. In ELISA: HbsAg (-), HBeAg (-), anti-HBsum total., Anti-HCV total. (-). According to polyhepatography (PHG), an increase in the base resistance was noted against a background of high amplitude rheographic curves. Violations of the hepatic hemodynamics are associated with a predominant violation of the venous outflow. Rheographic signs of sinusoidal intrahepatic hypertension. During the ABPM, the formation of a non-dipper blood pressure profile was noted. Rhythmocardiography presented signs of vagosympathetic imbalance during orthostatic testing and the preservation of the normotonic type of regulation in other positions. ECG - supraventricular extrasystole. Echo cardiography: an increase in the ejection fraction of the left ventricle. When conducting a liver scan, diffuse changes, hepatomegaly were noted. According to the data of an ultrasound dopplerographic duplex study of the abdominal organs, the following was found: the liver increased the size of the right lobe of 215 mm (+ 6.0), the size of the left lobe of 170 mm (+ 6.0 cm). The structure of the liver is heterogeneous, moderately diffuse. The spleen is not enlarged - 106/50 mm. Portal vein - 10.6 mm, not expanded. Splenic vein - 6.2 mm, not dilated. When dopplerography of the vessels of the liver: the vascular tree is uniform, moderately saturated, the venous component predominates. The blood flow through the lobar veins is bidirectional, along the segmental veins - linear, unidirectional. The speed characteristics of blood flow in the veins are from 8 to 14 cm / s. The diameters of the veins of the liver at the level of inflow into the inferior vena cava are 4 and 5 mm, the blood flow is bi-directional. It was not possible to detect blood flow in the hepatic arteries due to poor visualization of the arteries. Pancreas: head 24.2, body 16.6, tail 15 mm. The contours are even. The structure of reduced echogenicity with areas of fibrosis, no focal changes. Wirsung duct 2.4 mm in diameter. Choledoch 3.7 mm. Gall bladder: the wall is thickened to 0.4 cm, there are no calculi. Conclusion: hepatomegaly, diffuse changes in the liver, diffuse changes in the pancreas. Ultrasound - signs of hr. cholecystitis. The patient underwent a liver biopsy. Morphological studies showed: lobular structure preserved, large-droplet, fatty degeneration of hepatocytes, pronounced polymorphism of nuclei, a few focal necrosis of hepatocytes. Fibrosis of the central veins. Portal tracts are slightly expanded and fibrosed with moderate lymphomacrophagal infiltration. Hemosiderosis of the 1st degree with dusty granules of pigment. Orsein staining is negative.

The patient underwent drug therapy: intravenous drip of 5% glucose solution and vitamins of group B, C. Creon, LIV 52, tocopherol acetate was prescribed. Despite the ongoing therapy, no significant dynamics were obtained, in connection with which the patient was additionally prescribed a course of blood pressure against the background of the indicated drug therapy: 10 sessions daily on the device KAD-01-ACC "HOPE" in 10 cycles of 3 minutes, with a vacuum - 0.06 kg / cm ² with a pause of 1 min after each cycle. As a result of this complex therapy, the patient's condition improved significantly, weakness, nausea, a feeling of heaviness in the right hypochondrium and epigastric region, belching, bloating, and appetite returned to normal. Marked normalization of the color of the skin and mucous membranes, a reduction in the size of the liver. When polyhepatography was performed in dynamics, a positive dynamics was obtained, manifested by an improvement in venous outflow, a decrease in the rheographic signs of sinusoidal hypertension. Clinical and laboratory parameters improved: total protein - 73 g / l, albumin - 54%, gamma globulins - 36.3%, sublimate test - 1.6 ml, ALT - 17.1 mmol / l, bilirubin - 24, 8 μmol / l, ESR - 11 mm / h, CEC - 19.1.

EXAMPLE 2. Patient F., 40 years old. Diagnosis: chronic viral hepatitis C, replication phase with marked activity, grade 2 fibrosis with initial signs of portal hypertension. At admission, she complained of weakness, decreased performance, pain in the right hypochondrium, unstable chair. Sick for 3 years, when for the first time she began to notice a decrease in working capacity, the appearance of unmotivated weakness, increased fatigue, episodic pain in the right hypochondrium and epigastric region, associated mainly with physical and psychoemotional stress. I did not go to the doctor. Ultrasound examination showed hepatomegaly, thrombocytopenia, increased ESR were detected in a clinical blood test, and therefore the patient was examined and treated in a hospital. Objectively: upon admission, the condition is satisfactory, the skin is clean, normal in color, sclera subicteric. The pulse is 76 min ^-1 rhythmic. HELL 130/70 mm Hg Heart sounds are clear, rhythmic, the ratio of tones is not changed. The liver is enlarged, protrudes from the edge of the costal arch by 4 cm, the spleen is not palpable.

During the examination: red blood cells - 4.36 × 10 ¹² / l, hemoglobin - 132 g / l, color indicator - 0.92, white blood cells - 6.0 × 10 ⁹ / l, platelets - 153.8 × 10 ⁹ / l, ESR - 26 mm / h, AsAT - 0.48 mmol / L, AlAT - 2.04 mmol / L, bilirubin - 30.6 μmol / L, alkaline phosphatase - 100 U / L, GGTP - 77 U / L, thymol sample - 7.0 ALL, albumin - 48%, gamma globulins - 38.5%. HCV-RNA (++) in serum is positive by PCR, positive antibodies to hepatitis C virus (ELISA). Indicators of adaptive and nonspecific immunity: CD3 0.620 × 10 ⁹ / L, CD4 0.410 × 10 ⁹ / L, CD8 0.252 × 10 ⁹ / L, CD4 / CD8 - 1.62; CD72 0.192 × 10 ⁹ / l, CEC 142.38 units, IgG 21.4 g / l. The patient underwent PGT, where, against the background of an increase in basic resistance and a decrease in the amplitude of the rheographic curves, a distortion of the rheographic curves in the region of the right, left lobe of the liver and spleen was noted. Violations of intrahepatic hemodynamics are caused by a predominant violation of the venous inflow; signs of impaired venous outflow from the spleen. Inhibition of autonomic regulation with an increase in the role of humoral-metabolic influences in the sinus node was noted on the RCH. On the ECG - signs of left ventricular hypertrophy, lengthening of the QT interval. When conducting an ultrasound of the heart - signs of moderate hypertrophy of the left ventricle. FGDS - gastroduodenitis. According to the ultrasound, hepatomegaly was noted, signs of chronic cholecystitis, according to the data of ultrasound duplex dopplerography of the blood vessels of the liver, the liver was enlarged. right lobe 191 mm (+ 4.1 cm), cr. left lobe 128 (2.8 cm), the liver structure is heterogeneous, there are moderately diffuse changes in the liver. The spleen is not enlarged. When Doppler, the vascular tree is uniform, moderately saturated, the venous component predominates. Speed characteristics in arteries and veins correspond to normal values. Portal vein 15 mm wide, linear unidirectional blood flow. Conclusion: an increase in the liver due to both lobes of the liver, moderate diffuse changes, signs of portal hypertension. In a radioisotope study of the liver, hepatosplenomegaly, diffuse changes in the liver, signs of portal hypertension, accumulation of a radiopharmaceutical in the spleen up to 35%.

Morphological examination of the liver: lobular architectonics preserved, severe granular, hydropic and focal fatty degeneration of hepatocytes, moderate nuclear polymorphism. Common focal, stepwise and single bridging necrosis of hepatocytes. Separate portal tracts are moderately expanded, fibrosed in places with the formation of port-portal septa with dense lymphoid infiltration. The color for iron and orcein is positive. The histological picture of the liver corresponded to chronic hepatitis with a moderate degree of activity and fibrosis.

The patient underwent drug therapy: Intravenous drip of a 5% solution of glucose and vitamins of group B, C, tocopherol acetate, thymalin No. 10 v / m. Pancytrate 10000 was prescribed. In addition, a course of blood pressure was prescribed: 15 sessions daily against the background of the indicated medication in 15 cycles of 1 minute with a vacuum of 0.1 kg / cm ² with a 1 min pause after each cycle. After this therapy, the patient's condition improved significantly, weakness, a feeling of heaviness in the right hypochondrium and epigastric region disappeared, and appetite returned to normal. Objectively: normalizing the color of the skin and mucous membranes, reducing the size of the liver. During polyhepatography in dynamics, a positive dynamics was obtained, manifested by an improvement in venous flow, an increase in blood supply to the liver, a decrease in signs of presinusoidal hypertension and impaired hemodynamics of the spleen, and an improvement in clinical and laboratory parameters. Examination: red blood cells - 4.32 × 10 ¹² / l, hemoglobin - 131 g / l, white blood cells - 6.0 × 10 ⁹ / l, platelets - 173.8 × 10 ⁹ / l, ESR - 16 mm / h, AsAT - 0.45 mmol / L, AlAT - 0.64 mmol / L, bilirubin - 10.6 μmol / L, alkaline phosphatase - 86 U / L, GGTP - 67 U / L, thymol sample - 5.0 ALL, albumin - 58%, gamma globulins - 22.5%, CEC - 19.0 PCR RNA C (+) HCV (+).

EXAMPLE 3. Patient D., 39 years old. Diagnosis: mesangial-proliferative glomerulonephritis, remission, symptomatic arterial hypertension, CRF-1. Upon admission, she complained of weakness, headache, decreased appetite, and swelling of the face in the morning. From the anamnesis: proteinuria was first observed at 22 years of age during pregnancy. After birth, isolated proteinuria was occasionally observed. Daily protein loss of less than 1.0 g. Took ω ₃ fatty acids.

Objectively: upon admission, the condition is satisfactory, the skin is clean normal color. Pulse 86 min ^-1 , rhythmic. HELL 170/100 mm Hg Heart sounds are clear, rhythmic, the ratio of tones is not changed.

The liver is not enlarged, the spleen is not palpable. During the examination: red blood cells - 4.36 × 10 ¹² / l, hemoglobin - 132 g / l, color indicator - 0.92, white blood cells - 6.0 × 10 ⁹ / l, platelets - 153.8 × 10 ⁹ / l, ESR 26 mm / h, total protein - 60 g / l, AcAT - 0.48 mmol / l, AlAT - 2.04 mmol / l, bilirubin - 30.6 μmol / l, alkaline phosphatase - 100 U / l, GTPP - 77 IU / l, thymol sample - 6.0 ALL, albumin - 40%, gamma globulins - 38.5%, creatinine 0.18 mmol / l. In the general analysis of urine, isolated proteinuria was detected. Daily protein loss - 2.0 g. Indicators of adaptive and nonspecific immunity: CD3 0.510 × 10 ⁹ / L, CD4 0.490 × 10 ⁹ / L, CD8 0.356 × 10 ⁹ / L, CD4 / CD8 = 1.81, CEC - 242 , 38 units, IgG - 31.4 g / l. When conducting RCH, inhibition of autonomic regulation was noted with an increase in the role of humoral-metabolic influences in the sinus node. On the ECG - signs of left ventricular hypertrophy, lengthening of the QT interval. When conducting an ultrasound of the heart - signs of moderate left ventricular hypertrophy, an increase in the final systolic and diastolic volumes (CSR, BWW), stroke volume (UO), cardiac index (SI), minute volume of blood flow (IOC). According to the ultrasound, signs of chronic cholecystitis, diffuse changes in the kidneys were noted. When conducting morphological studies of the kidneys revealed: diffuse proliferation of mesangium cells, an increase in the mesangial matrix, glomerular basal is not changed. With immunofluorescence in the mesangium, IgG was detected. Conclusion: IgG nephropathy.

The patient underwent therapy: enalapril 5 mg 2 times a day, polyene 1 capsule 3 times a day, oily DUE F 1 capsule 2 times a day, tocopherol acetate No. 10 v / m. The course of blood pressure was prescribed: 13 sessions in the regime of 15 cycles of 2 minutes at a pressure of -0.1 kg / cm ² with 1 min pause after each cycle.

After completing the course of therapy, 10 patients noted an improvement in overall well-being, normalization of sleep and appetite, a decrease in weakness, swelling in the face, and normalization of blood pressure. During the Rayberg test, a decrease in protein loss to 1.2 g per day was noted. Creatinine levels decreased to 0.15 mmol / L.

Table 1 summarizes the results of an analysis of the dynamics of changes in blood serum in humans in the treatment of liver diseases. The table shows the results of an examination of three groups of people: healthy individuals (control group) and patients treated with the proposed and prototype (vita-phonotherapy against the background of drug therapy) methods. As can be seen from the table, the proposed method is more effective in comparison with the prototype in relation to bringing to normal the blood parameters indicated in examples 1-3.

Examples 4 to 5 illustrate the treatment of animals.

EXAMPLE 4. For the treatment of two outbred dogs suffering from parenchymal hepatitis, 2 hours after a single daily intake of essential 2 capsules, oral BP cycles were performed once for 30 minutes at a pressure of -0.1 kg / cm ² for 10 days. As a result of treatment, normalization of hepatic hemodynamics and improvement of hemodynamic parameters was noted, which is illustrated by the rheograms of figure 2, where the curves below show the uneven blood flow in dogs with stagnant phenomena before treatment, and the upper curves characterize the normalization of hemodynamics in the liver after treatment by the proposed method.

EXAMPLE 5. In a group of 5 cats (age 7-9 years) with a diagnosis of liver lipidosis, in addition to the basic symptomatic therapy, blood pressure sessions were used. 10 sessions were carried out daily for 3 cycles of 5 minutes with a vacuum of -0.02 to -0.1 kg / cm ² , a break of 30 seconds. 2 hours before the sessions of blood pressure, animals were given Lactofiltrum 1 tablet orally.

The results are presented in table.2. As can be seen from the table, at the end of blood pressure procedures, the clinical condition of the animals improved and the biochemical parameters of blood — alkaline phosphatase and bilirubin — were normalized from 105 to 28 IU / L and from 5.3 to 0.4 mg%, respectively.

Thus, the use of blood pressure in combination with drug therapy expands the arsenal of drugs used to treat liver diseases, increasing the effectiveness of treatment in relation to the normalization of physiological parameters. In addition, in relation to the treatment of animals, the new method is more technologically advanced, since, unlike the prototype, it does not require the almost impossible fixation of the emitter of physiotherapeutic effects on the patient’s body.

Table 1 The dynamics of changes in blood serum in humans in the treatment of liver diseases INDICATORS Control group (30 people) SUGGESTED METHOD (13 people) PROTOTYPE METHOD (15 people) Before treatment After treatment Before treatment After treatment Total protein (g / l) 70.80 ± 0.93 69.80 ± 1.18 74.20 ± 1.12 69.70 ± 1.11 72.50 ± 1.23 Albumin (g / l) 41.70 ± 1.08 37.10 ± 1.13 44.80 ± 1.28 35.45 ± 1.17 46.40 ± 1.34 Gamma globulins (%) 17.70 ± 0.63 24.50 ± 1.03 18.40 ± 0.65 23.80 ± 0.92 16.40 ± 0.74 Thymol Test (ALL) 15.30 ± 0.92 30.90 ± 1.39 18.40 ± 0.95 30.80 ± 1.46 22.40 ± 0.44 Sublimate test (ml) 1.90 ± 0.04 1.64 ± 0.05 1.88 ± 0.04 1.65 ± 0.05 1.78 ± 0.07 AsAT (mmol / l / h /) 0.34 ± 0.02 0.85 ± 0.10 0.40 ± 0.03 0.84 ± 0.08 0.70 ± 0.04 AlAT (mmol / l / h) 0.31 ± 0.02 2.66 ± 0.53 1.10 ± 0.13 2.57 ± 0.58 1,60 ± 0,15 Alkaline phosphatase (mmol / (h · l)) 1.25 ± 0.06 2.85 ± 0.11 1.95 ± 0.09 2.77 ± 0.16 2.00 ± 0.06 Total bilirubin (μmol / L) 14.50 ± 0.13 38.50 ± 4.76 17.90 ± 1.45 38.41 ± 5.25 22.90 ± 1.32 Cholesterol (mmol / L) 4.98 ± 0.22 5.07 ± 0.12 4.10 ± 0.10 5.08 ± 0.120 5.01 ± 0.088

table 2 Biochemical blood counts of cats with liver lipidosis INDICATOR BEFORE TREATMENT AFTER TREATMENT Alkaline phosphatase, IU / L 105.1 ± 1.2 27.5 ± 0.5 Bilirubin, mg% 5.3 ± 0.6 0.43 ± 0.02

Claims (1)

A method for the treatment of liver diseases, involving drug therapy in combination with a physiotherapeutic effect, characterized in that abdominal decompression is performed as a physiotherapeutic effect.

Images